Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection

Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection Kaitlyn Bader, Senior Editor NEWS PROVIDED BY Alphyn Biologics July 14, 2023 AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component. Read the Dermatology Times article…

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection NEWS PROVIDED BY Alphyn Biologics Jul 14, 2023, 07:30 ET Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis ANNAPOLIS, Md. and ASHEVILLE, N.C., July 14, 2023 /PRNewswire/ — Alphyn Biologics,…

Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis

Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 13, 2023, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis

Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis Heather Raglin, Editor NEWS PROVIDED BY Alphyn Biologics July 11, 2023 Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon. Read the Dermatology Times article here. CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com…

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Jul 10, 2023, 16:15 ET -Statistically significant improvements in IGA (Investigator Global Assessment) and EASI (Eczema Area and Severity Index) scores – Fast itch reduction by day 4 and sustained itch reduction – Body…